Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
Eur J Med Chem
; 274: 116532, 2024 Aug 05.
Article
em En
| MEDLINE
| ID: mdl-38805937
ABSTRACT
Histone H3 lysine 36 (H3K36) methylation is a typical epigenetic histone modification that is involved in various biological processes such as DNA transcription, repair and recombination in vivo. Mutations, translocations, and aberrant gene expression associated with H3K36 methyltransferases have been implicated in different malignancies such as acute myeloid leukemia, lung cancer, multiple myeloma, and others. Herein, we provided a comprehensive overview of the latest advances in small molecule inhibitors targeting H3K36 methyltransferases. We analyzed the structures and biological functions of the H3K36 methyltransferases family members. Additionally, we discussed the potential directions for future development of inhibitors targeting H3K36 methyltransferases.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Histona-Lisina N-Metiltransferase
/
Inibidores Enzimáticos
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article